1. A 74-year-old man with a 12-year history of Parkinson's disease develops progressive memory loss, attention fluctuations, and visuospatial difficulties. His neurologist confirms a diagnosis of Parkinson's disease dementia (PDD — cognitive decline meeting dementia criteria in a patient with established Parkinson's disease) and decides to initiate a cholinesterase inhibitor. Which of the following agents has an FDA indication specifically for Parkinson's disease dementia?
A) Donepezil
B) Rivastigmine
C) Galantamine
D) Memantine
E) Tacrine
ANSWER: B
Rationale:
Rivastigmine is the only cholinesterase inhibitor with an FDA indication specifically for Parkinson's disease dementia, supported by the pivotal EXPRESS trial (Emre et al., 2004), which demonstrated significant improvement in cognitive endpoints and clinician-rated global impression compared to placebo over 24 weeks. The transdermal patch formulation (9.5 mg/24 hr) is generally preferred over oral capsules because it produces more stable plasma levels and substantially fewer gastrointestinal adverse effects.
Option A: Option A is incorrect because donepezil, while widely used off-label and supported by some controlled data in PDD, does not carry a specific FDA approval for this indication.
Option C: Option C is incorrect because galantamine has the least evidence base in PDD specifically and lacks a PDD indication.
Option D: Option D is incorrect because memantine is an NMDA receptor antagonist approved for moderate-to-severe Alzheimer's disease dementia, not for PDD; it may be used off-label in some clinical situations but is not the FDA-approved agent for this diagnosis.
Option E: Option E is incorrect because tacrine, the first cholinesterase inhibitor approved, was withdrawn from clinical use due to hepatotoxicity and is no longer available.
2. A 71-year-old woman with Parkinson's disease develops persistent visual hallucinations and paranoid delusions that have not responded to tapering of her dopamine agonist. Her neurologist initiates pimavanserin (Nuplazid), the only FDA-approved medication for hallucinations and delusions associated with Parkinson's disease psychosis (PDP — psychotic symptoms occurring in the context of Parkinson's disease). Which of the following best describes the mechanism by which pimavanserin treats PDP without worsening motor function?
A) It blocks dopamine D2 receptors in the mesolimbic pathway while sparing the nigrostriatal pathway
B) It inhibits acetylcholinesterase, increasing cholinergic tone to suppress psychotic symptoms
C) It activates GABA-A receptors in the cortex, reducing excessive neuronal firing that drives hallucinations
D) It acts as an inverse agonist at serotonin 5-HT2A and 5-HT2C receptors with no dopamine receptor binding
E) It blocks norepinephrine reuptake in the prefrontal cortex, improving the signal-to-noise ratio in psychotic circuits
ANSWER: D
Rationale:
Pimavanserin is a selective inverse agonist at serotonin 5-HT2A and 5-HT2C receptors. It has no dopamine receptor binding affinity, which is the pharmacological basis for its ability to reduce psychotic symptoms without worsening the motor features of Parkinson's disease — motor worsening is the mechanism by which all dopamine-blocking antipsychotics are harmful in PD. The pivotal ACP-103-020 trial demonstrated a 37% reduction in the Scale for Assessment of Positive Symptoms adapted for PD (SAPS-PD) score compared to placebo after six weeks of treatment at 34 mg once daily.
Option A: Option A is incorrect because this describes the theoretical mesolimbic selectivity argument made for atypical antipsychotics, but pimavanserin does not work through dopamine receptor blockade at all — it has zero dopamine receptor affinity.
Option B: Option B is incorrect because acetylcholinesterase inhibition is the mechanism of rivastigmine and donepezil, which are used for cognitive symptoms in PDD, not for psychosis management.
Option C: Option C is incorrect because GABA-A receptor activation describes the mechanism of benzodiazepines and barbiturates, which are sedatives and have no specific antipsychotic efficacy in PDP.
Option E: Option E is incorrect because norepinephrine reuptake inhibition describes the mechanism of SNRIs and some tricyclic antidepressants (TCAs) used for depression in PD, not for psychosis.
3. A 68-year-old man with Parkinson's disease develops formed visual hallucinations — he sees animals and small people that he knows are not real. His current medications include carbidopa/levodopa, pramipexole, amantadine, and benztropine (an anticholinergic used to reduce tremor). His cognition is preserved. Before initiating any antipsychotic medication, what is the correct first pharmacological step in managing his psychosis?
A) Systematically taper and discontinue anticholinergic agents and amantadine
B) Immediately start pimavanserin 34 mg once daily
C) Switch carbidopa/levodopa to a controlled-release formulation to smooth dopamine levels
D) Begin low-dose quetiapine 25 mg at bedtime
E) Add a selective serotonin reuptake inhibitor to treat the underlying anxiety driving the hallucinations
ANSWER: A
Rationale:
The established management sequence for Parkinson's disease psychosis (PDP) requires a systematic reduction of the medication burden before antipsychotic drugs are added. The correct first step is to taper and discontinue anticholinergic agents (such as benztropine) and amantadine, both of which can precipitate or worsen psychosis through their effects on cholinergic and glutamatergic circuits. If psychosis persists after this step, dopamine agonists are reduced or discontinued next, followed by MAO-B inhibitors and COMT inhibitors, and finally levodopa dose reduction as a last resort among dopaminergic adjustments. This sequence prioritizes removing psychosis-triggering agents before introducing new drugs with their own adverse effect profiles.
Option B: Option B is incorrect because pimavanserin, while FDA-approved for PDP, is not the first intervention — medication review and reduction must precede antipsychotic initiation.
Option C: Option C is incorrect because switching to controlled-release levodopa does not address the primary drivers of psychosis in this case (anticholinergic and amantadine burden) and is not part of the standard PDP management sequence.
Option D: Option D is incorrect because quetiapine, even at low doses, is not the first-line step — medication reduction precedes antipsychotic addition.
Option E: Option E is incorrect because the hallucinations in PDP are not driven by anxiety; adding an SSRI is not part of the PDP management sequence and would not address the pharmacological contributors to psychosis.
4. A neurologist is discussing antipsychotic options for a patient with Parkinson's disease psychosis (PDP) who has not responded adequately to pimavanserin. She notes that one conventional antipsychotic does not worsen motor function at the doses used for PDP and has the strongest evidence base among conventional agents for this indication, though its use requires mandatory blood count monitoring. Which agent is she describing?
A) Haloperidol at low doses
B) Risperidone at low doses
C) Clozapine at low doses (12.5–50 mg/day)
D) Olanzapine at low doses
E) Quetiapine at standard doses
ANSWER: C
Rationale:
Clozapine at doses of 12.5–50 mg per day is the best-evidenced conventional antipsychotic for Parkinson's disease psychosis and does not worsen parkinsonism at these low doses. Its antipsychotic efficacy at PDP doses is thought to relate to its complex receptor pharmacology, which includes very low D2 receptor occupancy compared to the doses used in schizophrenia. The major barrier to its widespread use is the requirement for mandatory white blood cell monitoring due to the risk of agranulocytosis — a potentially fatal reduction in neutrophil count. This monitoring requirement is managed through a REMS (Risk Evaluation and Mitigation Strategy) program in the United States.
Option A: Option A is incorrect because haloperidol is a high-potency first-generation antipsychotic with strong D2 blockade that causes severe and potentially irreversible motor worsening in PD; it is contraindicated.
Option B: Option B is incorrect because risperidone, despite being an atypical antipsychotic, has sufficient D2 affinity to cause significant motor worsening in PD and should not be used.
Option D: Option D is incorrect because olanzapine causes unacceptable motor worsening in PD in controlled trials and is not recommended.
Option E: Option E is incorrect because quetiapine has less motor risk than risperidone but more than clozapine or pimavanserin, and its efficacy data in PDP are limited; it is sometimes used clinically but is not the best-evidenced agent.
5. A hospitalized patient with Parkinson's disease develops acute delirium. The overnight team considers prescribing an antipsychotic for agitation. Which of the following correctly identifies the pharmacological reason why most antipsychotic agents are contraindicated in patients with Parkinson's disease?
A) Most antipsychotics inhibit acetylcholinesterase, increasing cholinergic tone and worsening both tremor and rigidity
B) Most antipsychotics block norepinephrine alpha-1 receptors, causing severe orthostatic hypotension that is especially dangerous in PD
C) Most antipsychotics activate serotonin 5-HT1A receptors in the basal ganglia, directly suppressing dopaminergic output and worsening motor control
D) Most antipsychotics inhibit COMT (catechol-O-methyltransferase), reducing levodopa conversion and decreasing the therapeutic window
E) Most antipsychotics block dopamine D2 receptors, directly antagonizing the dopaminergic replacement therapy that controls PD motor symptoms
ANSWER: E
Rationale:
The vast majority of antipsychotic agents — both first-generation (typical) agents such as haloperidol and chlorpromazine, and most second-generation (atypical) agents such as risperidone and olanzapine — exert their antipsychotic effects primarily through blockade of dopamine D2 receptors. In Parkinson's disease, motor symptoms result from depletion of dopaminergic neurons in the substantia nigra, and the pharmacological management of motor symptoms depends on dopamine replacement or dopamine receptor stimulation. D2 receptor blockade directly antagonizes this therapeutic mechanism, causing severe and potentially irreversible worsening of rigidity, bradykinesia, and postural instability. This is why antipsychotics that lack significant D2 blockade — pimavanserin and low-dose clozapine — are the agents of choice for PDP.
Option A: Option A is incorrect because antipsychotics do not inhibit acetylcholinesterase; acetylcholinesterase inhibition is the mechanism of cholinesterase inhibitors used for dementia.
Option B: Option B is incorrect because while many antipsychotics do have alpha-1 blocking properties causing orthostatic hypotension, this is not the primary reason they are contraindicated in PD — the motor worsening from D2 blockade is the defining safety concern.
Option C: Option C is incorrect because antipsychotics do not activate 5-HT1A receptors to suppress dopaminergic output; the pharmacological mechanism of motor worsening is D2 blockade, not serotonin receptor activation.
Option D: Option D is incorrect because antipsychotics are not COMT inhibitors; COMT inhibitors (entacapone, tolcapone) are antiparkinson adjuncts that extend levodopa action.
6. Depression affects approximately 35% of patients with Parkinson's disease and arises in part from intrinsic degeneration of serotonergic and noradrenergic neurons — not solely from reactive sadness about the diagnosis. The SIC trial (Study of Antidepressants in PD) evaluated antidepressant efficacy in this population. Which of the following findings from the SIC trial is correct?
A) Sertraline was the most effective antidepressant tested and is now considered first-line for PD depression
B) Both paroxetine and venlafaxine XR significantly reduced depression scores compared to placebo, with venlafaxine showing a numerically larger effect size
C) Tricyclic antidepressants outperformed all SSRIs and SNRIs tested, establishing nortriptyline as the first-line agent for PD depression
D) No antidepressant tested achieved a statistically significant reduction in depression scores, calling into question the use of pharmacotherapy for PD depression
E) Bupropion was the only agent to show benefit, attributed to its mild dopaminergic activity enhancing the antiparkinson regimen
ANSWER: B
Rationale:
The SIC trial compared paroxetine (an SSRI) and venlafaxine XR (an SNRI — serotonin-norepinephrine reuptake inhibitor) to placebo in patients with Parkinson's disease and depression. Both active agents significantly reduced depression scores compared to placebo, with venlafaxine XR showing a numerically larger effect size, supporting its use as a first-line agent for PD depression. SSRIs and SNRIs are the most widely prescribed first-line antidepressants in PD given their tolerability profile.
Option A: Option A is incorrect because sertraline was not the agent tested in the SIC trial; the trial evaluated paroxetine and venlafaxine XR specifically.
Option C: Option C is incorrect because while tricyclic antidepressants (TCAs) such as nortriptyline have shown efficacy in PD depression in controlled trials and may benefit pain and sleep as additional effects, the SIC trial did not establish TCAs as superior, and their anticholinergic adverse effects make them poorly tolerated in older patients and those with cognitive impairment.
Option D: Option D is incorrect because both antidepressants tested in the SIC trial did achieve statistically significant reductions in depression scores compared to placebo.
Option E: Option E is incorrect because bupropion was not part of the SIC trial comparison, and while its mild dopaminergic activity is sometimes cited as a theoretical rationale, it is not established as the only effective antidepressant in PD.
7. A 72-year-old woman with Parkinson's disease has treatment-resistant depression that has not responded to two SSRI trials. She also has chronic musculoskeletal pain and disrupted sleep. Her neurologist considers nortriptyline, a tricyclic antidepressant (TCA — an older class of antidepressants that block reuptake of both serotonin and norepinephrine). Which of the following accurately describes the risk-benefit profile of TCAs in PD depression?
A) TCAs are contraindicated in all patients with PD because they block dopamine reuptake and directly interfere with levodopa therapy
B) TCAs are preferred over SSRIs in PD depression because they have no effect on the serotonergic system and therefore carry no risk of serotonin syndrome with MAO-B inhibitors
C) TCAs have no evidence base in PD depression and should be reserved only for treatment-resistant cases where all other classes have failed
D) TCAs have demonstrated efficacy in controlled trials for PD depression and may additionally benefit pain and sleep, but their anticholinergic adverse effects make them poorly tolerated in older patients and those with cognitive impairment
E) TCAs are the safest antidepressant choice in cognitively impaired PD patients because their anticholinergic effects reduce drooling and urinary urgency without worsening cognition
ANSWER: D
Rationale:
Tricyclic antidepressants such as nortriptyline have demonstrated efficacy in controlled trials for depression in Parkinson's disease and offer the additional benefit of improving pain and sleep quality — useful co-morbidities in this population. However, their anticholinergic adverse effects (dry mouth, constipation, urinary retention, tachycardia, and particularly cognitive impairment and delirium in older patients) make them poorly tolerated in elderly patients and those with concurrent cognitive impairment. In a patient with PD who already has cognitive vulnerability, TCAs require careful consideration and monitoring.
Option A: Option A is incorrect because TCAs do not block dopamine reuptake in a clinically significant way that interferes with levodopa therapy; their reuptake inhibition profile is primarily serotonergic and noradrenergic.
Option B: Option B is incorrect because TCAs do act on the serotonergic system and do carry a risk of serotonin syndrome in combination with MAO-B inhibitors at higher doses; the combination requires monitoring and caution.
Option C: Option C is incorrect because TCAs do have a valid evidence base in PD depression from controlled trials — the statement that they have "no evidence base" is factually wrong.
Option E: Option E is incorrect and dangerous: anticholinergic effects worsen cognitive function in PD patients, particularly those with existing cognitive impairment, and can precipitate delirium; they do not benefit cognition.
8. A 65-year-old man with Parkinson's disease tells his physician that he experiences episodes of intense anxiety, sweating, inner restlessness, and dysphoria that occur predictably about 30 minutes before his scheduled carbidopa/levodopa dose and resolve within 20 minutes of taking it. A primary care colleague has proposed starting a benzodiazepine. What is the most appropriate interpretation of these symptoms and the correct pharmacological response?
A) These symptoms represent generalized anxiety disorder that has been unmasked by the psychological stress of living with Parkinson's disease; an SSRI is the preferred pharmacological treatment
B) These symptoms are consistent with dopamine dysregulation syndrome and indicate that the patient's levodopa dose is too high and should be reduced
C) These symptoms represent non-motor wearing-off — a predictable manifestation of sub-therapeutic levodopa levels — and the primary intervention is levodopa regimen optimization, not anxiolytic addition
D) These symptoms represent a serotonin-related adverse effect from concurrent antidepressant use and should prompt immediate discontinuation of any serotonergic agents
E) These symptoms are a normal feature of advanced Parkinson's disease that does not respond to pharmacological adjustment and should be managed with behavioral techniques only
ANSWER: C
Rationale:
The pattern described — anxiety, sweating, inner restlessness, and dysphoria occurring predictably before a scheduled levodopa dose and resolving after taking it — is the hallmark of non-motor wearing-off. This phenomenon occurs as levodopa plasma concentrations fall below the therapeutic threshold, producing non-motor manifestations of dopamine deficiency in addition to motor symptoms. Recognizing this pattern is a critical clinical skill because these symptoms are frequently misattributed to a new psychiatric or autonomic disorder, leading to inappropriate prescribing of anxiolytics, antidepressants, or cardiovascular medications. The correct intervention is optimization of the dopaminergic regimen — typically by shortening the dosing interval, adding a COMT inhibitor, or adjusting the levodopa formulation — not the addition of anxiolytic agents.
Option A: Option A is incorrect because while PD patients are at increased risk for anxiety disorders, the time-locked relationship to the dosing cycle is the defining feature of non-motor wearing-off, not a coincidental anxiety disorder requiring independent treatment.
Option B: Option B is incorrect because dopamine dysregulation syndrome is associated with compulsive medication use and reward-related behaviors driven by excessive dopaminergic stimulation, not with predictable pre-dose dysphoria.
Option D: Option D is incorrect because the dose-cycle relationship makes a serotonin-related adverse effect unlikely, and there is no basis for attributing these symptoms to antidepressant use based on the information provided.
Option E: Option E is incorrect because non-motor wearing-off responds reliably to levodopa optimization in the majority of patients; dismissing it as unresponsive to pharmacological adjustment leaves the patient undertreated.
9. A 70-year-old woman with Parkinson's disease reports recurrent lightheadedness and two near-fainting episodes when she stands up from a chair. Her blood pressure drops from 138/82 mmHg supine to 96/60 mmHg after 1 minute of standing. She has already implemented non-pharmacological measures (increased salt and fluid intake, compression stockings, head-of-bed elevation) with only partial benefit. Her neurologist wants to add a pharmacological agent with FDA approval for neurogenic orthostatic hypotension (OH — a drop in blood pressure upon standing caused by failure of autonomic nervous system reflexes). Which of the following agents acts as a peripheral alpha-1 adrenergic agonist to raise standing blood pressure?
A) Midodrine
B) Droxidopa
C) Fludrocortisone
D) Pyridostigmine
E) Clonidine
ANSWER: A
Rationale:
Midodrine is a prodrug that is converted to desglymidodrine, a selective peripheral alpha-1 adrenergic agonist. By stimulating alpha-1 receptors in peripheral arterioles and veins, midodrine increases vascular resistance and venous return, raising standing blood pressure. It is FDA-approved for neurogenic orthostatic hypotension and is typically dosed at 2.5–10 mg two to three times daily, with the last dose taken at least four hours before bedtime to avoid supine hypertension during sleep.
Option B: Option B is incorrect because droxidopa is a synthetic amino acid that is converted to norepinephrine by aromatic L-amino acid decarboxylase; it raises blood pressure through norepinephrine-mediated vasoconstriction but is not an alpha-1 agonist — it is an FDA-approved norepinephrine precursor prodrug for neurogenic OH.
Option C: Option C is incorrect because fludrocortisone is a mineralocorticoid that expands plasma volume by promoting renal sodium and water retention; it does not act as an alpha-1 agonist and is used off-label for neurogenic OH rather than as an FDA-approved treatment.
Option D: Option D is incorrect because pyridostigmine is an acetylcholinesterase inhibitor used primarily for myasthenia gravis; it may have modest benefit in neurogenic OH through enhanced ganglionic transmission but is not an alpha-1 agonist and is not FDA-approved for this indication.
Option E: Option E is incorrect because clonidine is a central alpha-2 agonist that reduces sympathetic outflow and lowers blood pressure; it would worsen orthostatic hypotension rather than treat it.
10. A 73-year-old man with advanced Parkinson's disease has troublesome sialorrhea (excessive drooling — which in PD results from impaired swallowing automaticity rather than true overproduction of saliva). His neurologist wants to prescribe an oral anticholinergic agent to reduce salivary output but is concerned about worsening his mild cognitive impairment. Which of the following anticholinergic agents is preferred in this situation because it does not cross the blood-brain barrier (BBB) and therefore produces minimal central nervous system adverse effects?
A) Benztropine
B) Trihexyphenidyl
C) Oxybutynin
D) Atropine
E) Glycopyrrolate
ANSWER: E
Rationale:
Glycopyrrolate is a quaternary ammonium anticholinergic agent. Its permanent positive charge prevents it from crossing the blood-brain barrier, which means it reduces peripheral cholinergic activity (including salivary secretion) without producing the central anticholinergic adverse effects — cognitive impairment, confusion, hallucinations, and delirium — that are the primary safety concern when using anticholinergics in cognitively vulnerable PD patients. Glycopyrrolate 1–2 mg two to three times daily is an appropriate choice for sialorrhea in this population, or botulinum toxin injection into the parotid and submandibular glands provides an alternative with fewer systemic effects.
Option A: Option A is incorrect because benztropine is a tertiary amine anticholinergic that crosses the BBB readily and causes significant central adverse effects including cognitive impairment, hallucinations, and delirium — it is generally contraindicated in PD patients with cognitive impairment.
Option B: Option B is incorrect because trihexyphenidyl is also a tertiary amine anticholinergic with substantial CNS penetration and the same cognitive risks as benztropine.
Option C: Option C is incorrect because oxybutynin is a tertiary amine anticholinergic used primarily for overactive bladder; it has well-documented central anticholinergic effects and would worsen cognitive function.
Option D: Option D is incorrect because atropine is a tertiary amine alkaloid with excellent CNS penetration and prominent central anticholinergic effects; systemic atropine is not an appropriate choice for sialorrhea management in a cognitively impaired PD patient.
11. A 69-year-old woman with Parkinson's disease and mild cognitive impairment complains of urinary urgency and frequency that significantly affects her quality of life. Her neurologist wants to treat her overactive bladder symptoms pharmacologically but is concerned about worsening her cognition. Which of the following agents is preferred for overactive bladder in PD patients with cognitive impairment because it does not carry anticholinergic cognitive risk?
A) Oxybutynin extended-release
B) Tolterodine
C) Mirabegron
D) Solifenacin
E) Hyoscyamine
ANSWER: C
Rationale:
Mirabegron is a beta-3 adrenoreceptor agonist that relaxes the detrusor muscle of the bladder during the filling phase, reducing urgency and frequency without any anticholinergic mechanism. Because it does not block muscarinic receptors, it does not carry the cognitive risk that is the primary concern when managing bladder symptoms in PD patients with cognitive impairment. In contrast, the anticholinergic bladder agents — oxybutynin, tolterodine, solifenacin, and others — all carry varying degrees of CNS anticholinergic burden and are associated with cognitive worsening, particularly in older patients and those with existing cognitive vulnerability.
Option A: Option A is incorrect because oxybutynin, even in its extended-release formulation, has significant anticholinergic CNS effects and is among the highest-burden anticholinergic agents on standard scoring scales; it should be avoided in PD patients with cognitive impairment.
Option B: Option B is incorrect because tolterodine is a muscarinic antagonist for overactive bladder and carries anticholinergic cognitive risk, though somewhat less than oxybutynin; it is still not preferred in cognitively vulnerable PD patients.
Option D: Option D is incorrect because solifenacin is a selective M3 muscarinic antagonist used for overactive bladder; while it has less CNS penetration than oxybutynin, it still carries anticholinergic burden and is not the preferred agent in this population.
Option E: Option E is incorrect because hyoscyamine is a tertiary amine anticholinergic with high CNS penetration and should be avoided in any PD patient with cognitive impairment.
12. A 67-year-old man with Parkinson's disease is brought in by his wife, who reports that he has been acting out his dreams during sleep — he shouts, kicks, and once fell out of bed. Polysomnography confirms REM sleep behavior disorder (RBD — a parasomnia characterized by loss of normal skeletal muscle atonia during REM sleep, resulting in dream enactment behavior). He has no significant cognitive impairment. Which of the following correctly describes the first-line pharmacological treatment for RBD in this patient and the preferred alternative in cognitively impaired patients?
A) Zolpidem is first-line for RBD and is equally appropriate regardless of cognitive status because it selectively promotes sleep without affecting REM atonia
B) Clonazepam 0.25–1.0 mg at bedtime is the most widely used treatment for RBD; melatonin 3–12 mg at bedtime is an alternative preferred in patients with cognitive impairment or high fall risk
C) Low-dose quetiapine is the preferred pharmacological treatment for RBD because it suppresses REM sleep and eliminates dream enactment behavior without cognitive risk
D) MAO-B inhibitors such as selegiline are the treatment of choice for RBD because they reduce the dopaminergic fluctuations that trigger abnormal REM motor activity
E) RBD in PD does not respond to any pharmacological intervention and management is limited to environmental safety measures
ANSWER: B
Rationale:
Clonazepam 0.25–1.0 mg at bedtime is the most widely used pharmacological treatment for RBD, reducing the frequency and severity of enactment behavior in the majority of patients, though the evidence is largely observational. Its mechanism in RBD is not fully established but likely involves enhancement of GABA-mediated inhibition in brainstem circuits that control motor activity during REM sleep. In patients with concurrent cognitive impairment or those at high fall risk, melatonin 3–12 mg at bedtime is the preferred alternative because it carries fewer risks of cognitive impairment, excessive sedation, and falls than clonazepam.
Option A: Option A is incorrect because zolpidem (a non-benzodiazepine GABA-A modulator) does not reliably treat RBD and has significant risks of complex sleep behaviors, falls, and cognitive impairment; it is not a recommended treatment for RBD.
Option C: Option C is incorrect because quetiapine, while sometimes used at low doses for insomnia in PD, does not specifically suppress the abnormal REM motor behavior that characterizes RBD and is not a recommended treatment for this condition.
Option D: Option D is incorrect because MAO-B inhibitors are used for motor symptoms in PD and do not have an established role in treating RBD; there is no mechanism by which they would reliably restore REM atonia.
Option E: Option E is incorrect because both clonazepam and melatonin have demonstrated clinical benefit for RBD in observational studies and clinical practice, and pharmacological treatment combined with environmental safety measures is the standard approach.
13. A 64-year-old man with Parkinson's disease on pramipexole and carbidopa/levodopa reports falling asleep involuntarily during the day, including once while driving. He rates his daytime sleepiness as severely impairing. His neurologist explains that excessive daytime sleepiness (EDS) in PD is multifactorial, reflecting both intrinsic neurodegeneration of hypocretin/orexin neurons and sedative effects of certain dopaminergic medications. Which of the following is the most widely used pharmacological treatment for EDS in PD, with randomized trial evidence supporting improvement in subjective daytime sleepiness?
A) Amphetamine salts, which restore dopaminergic tone in wake-promoting circuits
B) Sodium oxybate, which consolidates nocturnal sleep and thereby reduces daytime sleepiness
C) Methylphenidate, which blocks dopamine and norepinephrine reuptake to promote wakefulness
D) Modafinil, a wake-promoting agent whose exact mechanism involves orexin circuit activation and reduced GABA release in wake-promoting regions
E) Caffeine at high doses, which blocks adenosine A2A receptors to promote wakefulness and may have neuroprotective properties in PD
ANSWER: D
Rationale:
Modafinil 100–400 mg in the morning is the most widely used pharmacological treatment for excessive daytime sleepiness in Parkinson's disease, with randomized controlled trial evidence supporting improvement in subjective sleepiness scores, though objective sleep architecture improvements have been less consistently demonstrated. Its mechanism is not fully characterized but involves modulation of hypothalamic orexin circuits, histaminergic pathways, and reduced GABA release in arousal-relevant regions. The neurologist should also consider whether pramipexole — one of the more sedating dopamine agonists — is a primary contributor to this patient's EDS, and whether a switch to a less sedating formulation or agent is appropriate.
Option A: Option A is incorrect because amphetamine salts are not used as first-line treatment for EDS in PD; they carry cardiovascular risks and have not been established as the standard pharmacological approach in this population.
Option B: Option B is incorrect because sodium oxybate (gamma-hydroxybutyrate, Schedule III) has been evaluated in PD and does improve nocturnal sleep consolidation, but its complex distribution requirements under a REMS program and Schedule III classification limit widespread use; it is not the most widely used agent.
Option C: Option C is incorrect because while methylphenidate has some evidence for fatigue in PD (as opposed to EDS), modafinil has the more established evidence base and broader use for EDS specifically.
Option E: Option E is incorrect because while caffeine and adenosine A2A antagonism have been studied for neuroprotective and motor effects in PD, caffeine at standard or high doses is not the established pharmacological treatment for EDS and is not used in clinical practice as a first-line therapy for this indication.
14. A 70-year-old woman with Parkinson's disease develops restless legs syndrome (RLS — an unpleasant urge to move the legs, typically worse at rest and in the evening, relieved by movement) that is not adequately controlled by her existing antiparkinson regimen. Her neurologist considers adding low-dose pramipexole specifically for RLS but mentions a significant long-term risk associated with dopamine agonist therapy for RLS. What is this risk, and which alternative drug class avoids it?
A) Augmentation — a paradoxical worsening and earlier onset of RLS symptoms with prolonged dopamine agonist use; alpha-2-delta calcium channel ligands (gabapentin enacarbil or pregabalin) are preferred because they do not carry augmentation risk
B) Serotonin syndrome — an interaction between pramipexole and any serotonergic antidepressant; alpha-2-delta ligands do not interact with serotonin and are therefore safer in patients on SSRIs
C) Impulse control disorder — compulsive gambling, hypersexuality, or binge eating triggered by dopamine agonist use; opioids at low doses are preferred because they have no dopaminergic mechanism and do not trigger impulse control symptoms
D) Dyskinesia — involuntary movements identical to levodopa-induced dyskinesia that develop after prolonged RLS doses of pramipexole; gabapentinoids are free of this risk
E) Rapid tolerance — RLS symptoms become completely refractory to all doses of pramipexole within six months; switching to rotigotine transdermal patch resets tolerance and is the preferred rescue strategy
ANSWER: A
Rationale:
Augmentation is the most clinically important long-term complication of dopamine agonist therapy for restless legs syndrome. It is characterized by a paradoxical worsening of RLS — symptoms begin earlier in the day, spread to previously unaffected body parts, and may become more intense — despite dose escalation. This creates a cycle where increasing doses are needed to control symptoms that are worsening because of the treatment itself. Alpha-2-delta calcium channel ligands, specifically gabapentin enacarbil and pregabalin, are increasingly preferred for RLS because they do not carry augmentation risk. Their mechanism involves binding to the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release in RLS-relevant circuits. The trade-off is that they add sedation and fall risk, which is a relevant consideration in the PD population.
Option B: Option B is incorrect because serotonin syndrome is not a recognized complication of pramipexole use for RLS; pramipexole acts on D2/D3 receptors and does not directly interact with the serotonin system in a way that produces serotonin syndrome.
Option C: Option C is incorrect because while impulse control disorders are a genuine concern with dopamine agonists in PD, opioids are not the preferred alternative for RLS in PD patients — they carry sedation, constipation, and fall risks that are amplified in this population; gabapentinoids are the preferred alternative.
Option D: Option D is incorrect because dyskinesia in PD is a complication of long-term levodopa therapy, not of dopamine agonists used at RLS doses; it is not the primary risk cited for pramipexole use in RLS.
Option E: Option E is incorrect because rapid complete tolerance to pramipexole within six months is not a recognized phenomenon in RLS management; augmentation, not tolerance in this sense, is the documented long-term complication.
15. A 75-year-old man with Parkinson's disease reports waking multiple times per night because he cannot turn over in bed — he lies rigid and unable to reposition himself until he is physically turned by his wife. He is also stiff and barely able to move for the first hour after waking each morning. His current antiparkinson regimen uses immediate-release carbidopa/levodopa three times daily, with the last dose at 6 PM. What pharmacological intervention most directly addresses the nocturnal motor problem driving his sleep disruption?
A) Adding zolpidem 5 mg at bedtime to promote deeper sleep and reduce nocturnal arousals
B) Starting melatonin 5 mg at bedtime to normalize the disrupted circadian rhythm common in PD
C) Adding low-dose quetiapine 12.5 mg at bedtime to provide sedation and reduce nighttime agitation
D) Initiating a dopamine agonist (pramipexole) at bedtime to stimulate dopamine receptors throughout the night
E) Switching the evening carbidopa/levodopa dose to a controlled-release formulation taken at bedtime to maintain therapeutic levodopa levels through the night
ANSWER: E
Rationale:
The patient's inability to turn in bed at night and severe early-morning akinesia are classic manifestations of nocturnal akinesia — loss of dopaminergic tone during the long overnight interval when no levodopa is taken. The direct pharmacological solution is to provide sustained levodopa coverage through the sleep period by administering a controlled-release (CR) carbidopa/levodopa formulation at bedtime. CR carbidopa/levodopa has a slower absorption profile and extended duration of action compared to immediate-release formulations, maintaining plasma levodopa levels at a therapeutic concentration for a longer period overnight. This directly addresses the motor symptom that is fragmenting his sleep, rather than adding a sedative that treats the symptom of waking without addressing its cause.
Option A: Option A is incorrect because zolpidem promotes sleep initiation and reduces arousals through GABA-A receptor modulation but does not address nocturnal akinesia — the patient's fundamental problem is that he cannot move, not that he cannot fall asleep.
Option B: Option B is incorrect because melatonin is a reasonable treatment for sleep initiation difficulty and circadian disruption in PD, but the dominant problem here is motor — nocturnal akinesia causing inability to turn — which melatonin does not address.
Option C: Option C is incorrect because low-dose quetiapine provides sedation and is sometimes used for PD insomnia, but like zolpidem it does not treat the underlying motor deficit causing the awakenings.
Option D: Option D is incorrect because dopamine agonists can produce significant sedation and do not provide the reliable motor coverage overnight that levodopa does; they are not the standard intervention for nocturnal akinesia, and adding a new dopamine agonist introduces impulse control and other adverse effect risks unnecessarily when a levodopa formulation change directly addresses the problem.
16. A 71-year-old woman with Parkinson's disease on carbidopa/levodopa reports significant pain in her left foot and calf that she describes as cramping, pulling, and sometimes burning. She notes that the pain is most intense in the early morning before her first levodopa dose and subsides about 30 minutes after taking it. A colleague suggests starting pregabalin for neuropathic pain. Before initiating any analgesic, what is the most important first clinical assessment in this patient?
A) Obtain an MRI of the lumbar spine to exclude radicular compression as the structural source of foot and calf pain before attributing the pain to Parkinson's disease
B) Determine whether the pain is fluctuation-related — occurring during off periods and resolving in on periods — because if so, levodopa regimen optimization is the primary intervention rather than analgesic escalation
C) Order nerve conduction studies to classify the pain as small-fiber neuropathic versus large-fiber neuropathic, as this distinction determines whether pregabalin or duloxetine is the more appropriate agent
D) Assess the patient's fall risk before prescribing pregabalin, because gabapentinoids are the most dangerous analgesic class in the PD population due to their propensity to cause sudden-onset sleep episodes
E) Determine whether the pain is musculoskeletal or neuropathic in character using a validated pain questionnaire before selecting a drug class, as the pharmacological approach differs entirely between these two subtypes
ANSWER: B
Rationale:
In Parkinson's disease, the most important first clinical step when evaluating pain is to determine whether it is fluctuation-related — that is, whether it occurs during off periods (when levodopa levels are sub-therapeutic) and resolves during on periods (when dopaminergic coverage is adequate). The pattern in this patient — pain worst in the early morning before the first dose, resolving after taking levodopa — is classic for off-period dystonic or musculoskeletal pain that is dopaminergically driven. The correct intervention is optimization of the levodopa regimen (for example, by adding a bedtime controlled-release dose or a COMT inhibitor to extend coverage) rather than adding an analgesic. Only pain that persists across motor states — in both on and off periods — warrants non-dopaminergic analgesic therapy. Treating fluctuation-related pain with pregabalin would address the wrong mechanism and add adverse effects unnecessarily.
Option A: Option A is incorrect because while lumbar radiculopathy should eventually be considered if the pain does not respond to levodopa optimization, the time-locked relationship to the dosing cycle strongly suggests fluctuation-related pain and is the first priority to evaluate and address.
Option C: Option C is incorrect because nerve conduction studies would be relevant if neuropathic etiology were confirmed, but the off-period pattern must be evaluated and addressed first.
Option D: Option D is incorrect because while fall risk is always relevant in PD, it is not the most important first step before deciding whether an analgesic is even needed; the fluctuation-related assessment takes precedence and may eliminate the need for pregabalin entirely.
Option E: Option E is incorrect because the musculoskeletal vs. neuropathic distinction, while clinically useful, is secondary to the fluctuation-relatedness assessment — off-period pain of any subtype responds to levodopa optimization and does not require analgesic selection at that stage.
17. A 73-year-old man with Parkinson's disease is maintained on rasagiline (an MAO-B inhibitor — a drug that blocks monoamine oxidase type B, which metabolizes dopamine in the brain) for motor symptom control. He develops chronic low back pain, and a colleague proposes adding tramadol for analgesia. Why is tramadol specifically contraindicated in this patient?
A) Tramadol is a weak opioid that competitively inhibits levodopa absorption at the gastrointestinal level, reducing the bioavailability of carbidopa/levodopa and worsening motor control
B) Tramadol causes dose-dependent D2 receptor blockade at analgesic doses, directly antagonizing the dopaminergic mechanism of rasagiline and worsening parkinsonism
C) Tramadol inhibits serotonin and norepinephrine reuptake in addition to its opioid activity, creating a risk of serotonin syndrome or seizures when combined with MAO-B inhibitors
D) Tramadol induces CYP2D6 (a liver enzyme involved in drug metabolism), accelerating rasagiline metabolism and reducing its plasma concentration below therapeutic levels
E) Tramadol blocks norepinephrine alpha-2 receptors peripherally, exacerbating the orthostatic hypotension that is already common in patients on dopaminergic therapy
ANSWER: C
Rationale:
Tramadol has a dual mechanism of action: it is a weak mu-opioid receptor agonist and simultaneously inhibits the reuptake of both serotonin and norepinephrine. This serotonergic component creates a clinically important interaction with MAO-B inhibitors such as rasagiline and selegiline. Selective MAO-B inhibitors at therapeutic doses act predominantly on MAO-B rather than MAO-A (the isoform that metabolizes serotonin), and the published clinical experience indicates that MAO-B inhibitors combined with serotonergic agents are generally well tolerated, with serotonin syndrome occurring rarely; the precise mechanism of the rare events is not firmly established. Nonetheless, the combination of tramadol's serotonin reuptake inhibition with MAO-B inhibition is recognized to carry a real, if uncommon, risk of serotonin syndrome — characterized by hyperthermia, agitation, clonus, tremor, and hyperreflexia — and tramadol additionally lowers the seizure threshold. Because tramadol carries this serotonergic liability and prescribing information cautions against combining it with MAO inhibitors, alternative analgesics without serotonergic activity are preferred, and any unavoidable serotonergic combination should use the lowest effective dose with monitoring for early signs of serotonin syndrome.
Option A: Option A is incorrect because tramadol does not meaningfully inhibit levodopa absorption at the gastrointestinal level; this is not a recognized pharmacokinetic interaction between tramadol and levodopa.
Option B: Option B is incorrect because tramadol does not have significant D2 receptor blocking activity; it is not a dopamine receptor antagonist and does not worsen parkinsonism through this mechanism.
Option D: Option D is incorrect because tramadol is metabolized by CYP2D6, but it does not induce this enzyme; moreover, rasagiline metabolism is primarily through CYP1A2, not CYP2D6, making this a pharmacokinetically inaccurate distractor.
Option E: Option E is incorrect because tramadol does not block norepinephrine alpha-2 receptors; norepinephrine reuptake inhibition (which is its noradrenergic mechanism) would, if anything, tend to support blood pressure rather than cause orthostatic hypotension.
18. A 67-year-old man with Parkinson's disease rates fatigue as his most disabling symptom, more so than his motor difficulties. He describes persistent central tiredness and lack of mental energy that is present even on days when his motor function is well controlled and his mood is normal. His sleep quality is adequate. His neurologist distinguishes this as central fatigue in PD — a distinct phenomenon separate from excessive daytime sleepiness and depression. Which of the following best characterizes the pharmacological treatment of central fatigue in PD?
A) Central fatigue in PD is poorly responsive to standard antidepressants; methylphenidate at low doses has controlled trial evidence for PD fatigue, and modafinil may benefit some patients
B) Central fatigue in PD responds reliably to SSRI therapy because it is fundamentally driven by serotonergic depletion in the raphe nuclei, making antidepressants the first-line treatment
C) Levodopa dose escalation reliably resolves central fatigue in PD because it directly restores dopaminergic tone in the cortical circuits responsible for motivated behavior and arousal
D) Amantadine is the best-evidenced treatment for central fatigue in PD because its glutamate antagonism and dopamine-releasing properties both address the neurobiological substrate of fatigue
E) Central fatigue in PD has no pharmacological treatment and should be managed exclusively with structured exercise programs and cognitive behavioral therapy
ANSWER: A
Rationale:
Central fatigue in Parkinson's disease is a recognized and distinct non-motor symptom that is poorly responsive to standard antidepressant therapy, even though it frequently coexists with depression. This distinguishes it from reactive fatigue or anhedonia, where treating depression reliably improves energy. Among pharmacological options, methylphenidate at low doses has been evaluated in randomized trials and shows some benefit for PD fatigue, thought to reflect its dopaminergic and noradrenergic stimulant effects on arousal and motivational circuits. Modafinil, primarily used for excessive daytime sleepiness, may also benefit fatigue in subgroups. Rivastigmine may improve fatigue in patients with Parkinson's disease dementia as part of its broader effects on cholinergic arousal systems.
Option B: Option B is incorrect because central fatigue in PD is not reliably responsive to SSRIs — it is not fundamentally a serotonergic depletion syndrome, and clinical experience and trial data consistently show that antidepressants alone do not resolve PD fatigue.
Option C: Option C is incorrect because while optimization of motor control can reduce fatigue that is secondary to the physical effort of moving against rigidity, central fatigue does not reliably respond to levodopa dose escalation — the central fatigue circuit is not simply dopamine deficiency in motor pathways.
Option D: Option D is incorrect because amantadine does not have the best evidence base for central fatigue in PD; its primary roles are in treating early motor symptoms and levodopa-induced dyskinesia, not fatigue specifically.
Option E: Option E is incorrect because pharmacological options do exist for PD fatigue — methylphenidate and modafinil — and dismissing all pharmacotherapy in favor of exercise and behavioral therapy alone leaves a treatable symptom unaddressed.
19. A 78-year-old man with advanced Parkinson's disease is admitted to a general medical ward for a urinary tract infection. The admitting team, unfamiliar with his antiparkinson regimen, places him on NPO status (nothing by mouth) ahead of a planned procedure and does not arrange alternative delivery of his carbidopa/levodopa. By morning he is rigid, unable to swallow, minimally verbal, and has developed a fever. Which of the following best explains this clinical deterioration and the critical management principle it illustrates?
A) The patient has developed neuroleptic malignant syndrome from an antipsychotic prescribed for delirium, which presents identically to acute akinesia and requires immediate dantrolene therapy
B) The infection has precipitated a PD disease crisis unrelated to medication timing, and the appropriate response is IV antibiotics and supportive care without medication adjustment
C) Prolonged NPO status has caused metabolic derangements (hyponatremia, hypoglycemia) that are specifically toxic to dopaminergic neurons, precipitating irreversible disease progression
D) Withholding dopaminergic medications in a hospitalized PD patient causes acute akinesia that can progress to aspiration pneumonia and death within hours; dopaminergic medications must never be withheld and require time-critical reinstatement via nasogastric tube or parenteral route
E) The patient has developed a hypertensive crisis from the interaction between the urinary tract infection and his MAO-B inhibitor; blood pressure control is the immediate priority
ANSWER: D
Rationale:
Withholding dopaminergic medications in hospitalized patients with Parkinson's disease is one of the most dangerous errors in hospital pharmacological management. As levodopa plasma levels fall, severe akinesia, rigidity, and dysphagia develop rapidly — often within hours of a missed dose in patients with advanced disease. Profound dysphagia combined with inability to protect the airway creates an immediate aspiration risk, and the clinical picture can escalate to aspiration pneumonia, respiratory failure, and death with alarming speed. The principle is absolute: dopaminergic medications must never be withheld in a hospitalized PD patient without immediate alternative delivery planning (nasogastric administration, apomorphine injection, or rotigotine transdermal patch). The admitting team must be made aware of this time-critical dependency at the point of admission.
Option A: Option A is incorrect because neuroleptic malignant syndrome (NMS) is typically triggered by antipsychotic use or abrupt dopaminergic withdrawal; without evidence that an antipsychotic was prescribed, this diagnosis is speculative and dantrolene is not the immediate first intervention — restoring dopaminergic medications is.
Option B: Option B is incorrect because the clinical deterioration is directly explicable by medication withdrawal, not by the infection alone; failing to restore the antiparkinson regimen while managing the infection would leave the proximate cause of deterioration unaddressed.
Option C: Option C is incorrect because NPO status does not cause metabolic toxicity specifically to dopaminergic neurons; the deterioration is pharmacological (levodopa withdrawal), not metabolic.
Option E: Option E is incorrect because a hypertensive crisis from MAO-B inhibitor interaction is not the mechanism described, and the clinical picture — rigidity, inability to swallow, minimal speech — is consistent with severe dopamine-deficiency akinesia, not a hypertensive emergency.
20. A 72-year-old woman with Parkinson's disease is admitted for an elective surgical procedure. Postoperatively she develops significant nausea and the anesthesia team orders metoclopramide as an antiemetic. The ward pharmacist flags this order. Why is metoclopramide specifically contraindicated in patients with Parkinson's disease, and what antiemetic agents are safe alternatives?
A) Metoclopramide is contraindicated because it is a potent MAO-A inhibitor that causes dangerous hypertensive crises when combined with the levodopa in carbidopa/levodopa; ondansetron and prochlorperazine are safe alternatives
B) Metoclopramide blocks dopamine D2 receptors both peripherally and centrally, worsening motor symptoms and potentially causing irreversible parkinsonism; domperidone or ondansetron are appropriate alternatives
C) Metoclopramide is contraindicated because it accelerates gastric emptying and causes rapid fluctuations in levodopa absorption, making plasma concentrations unpredictably toxic; droperidol is a safer antiemetic with no effect on gastric motility
D) Metoclopramide inhibits aromatic L-amino acid decarboxylase (the enzyme that converts levodopa to dopamine), preventing therapeutic conversion and rendering carbidopa/levodopa completely ineffective; prochlorperazine does not share this enzyme inhibition
E) Metoclopramide causes irreversible binding to the dopamine transporter in the striatum, permanently depleting synaptic dopamine stores in a manner that accelerates PD neurodegeneration; haloperidol is preferred because it does not bind the transporter
ANSWER: B
Rationale:
Metoclopramide is a dopamine D2 receptor antagonist that acts both peripherally (on the gut, to promote gastric emptying) and centrally (crossing the blood-brain barrier to block D2 receptors in the basal ganglia and chemoreceptor trigger zone). Central D2 blockade in a patient with Parkinson's disease directly antagonizes the dopaminergic mechanism of antiparkinson therapy and causes acute motor worsening — worsening rigidity, bradykinesia, and postural instability. Prolonged use can precipitate drug-induced parkinsonism that may be difficult to distinguish from PD progression and, in rare cases, may be irreversible. Domperidone is the preferred peripheral antiemetic in PD because it does not cross the blood-brain barrier at standard doses, providing gastrointestinal D2 blockade without central motor worsening. Ondansetron (a serotonin 5-HT3 antagonist) is also a safe antiemetic choice in PD.
Option A: Option A is incorrect because metoclopramide is not an MAO-A inhibitor; its mechanism is D2 receptor blockade, and prochlorperazine is also a D2 blocker contraindicated in PD for the same reason — it is not a safe alternative.
Option C: Option C is incorrect because while metoclopramide does accelerate gastric emptying (which can affect levodopa absorption kinetics), this is not the primary reason for its contraindication in PD — D2 receptor blockade causing motor worsening is; droperidol is also a D2 blocker and would not be an appropriate safe alternative.
Option D: Option D is incorrect because metoclopramide does not inhibit aromatic L-amino acid decarboxylase; this mechanism is not related to metoclopramide pharmacology.
Option E: Option E is incorrect because metoclopramide acts as a competitive D2 receptor antagonist, not as a dopamine transporter inhibitor; it does not irreversibly deplete synaptic dopamine stores; and haloperidol is a high-potency D2 blocker that is contraindicated in PD and is not a safe alternative.
21. A 77-year-old woman with Parkinson's disease and established dementia is admitted to hospital for a hip fracture. A review of her medication list reveals she is taking an overactive bladder agent, a first-generation antihistamine for sleep, and a proton pump inhibitor. Her daughter reports that her cognition has worsened significantly over the past three months. The treating team uses the Anticholinergic Cognitive Burden (ACB) scale — a validated tool that scores medications from 0 (no anticholinergic burden) to 3 (high anticholinergic burden with definite CNS effects) — to evaluate the medication list. Which of the following best describes the correct application of this principle in managing cognitively impaired PD patients?
A) The ACB scale applies only to medications with anticholinergic properties that are used for psychiatric indications; medications prescribed for somatic conditions (overactive bladder, sleep, gastric acid) are exempt because their doses are too low to reach the brain
B) In cognitively impaired PD patients, a medication review for anticholinergic burden should be performed only if the patient reports specific complaints of memory worsening; asymptomatic anticholinergic use does not require reassessment
C) Any medication with an ACB score above zero should be immediately discontinued in all PD patients regardless of cognitive status, because no degree of anticholinergic burden is acceptable in this population
D) The ACB scale is useful in Alzheimer's disease but not in Parkinson's disease dementia, because the cholinergic deficit in PDD is already fully compensated by rivastigmine and additional anticholinergic burden carries no further cognitive risk
E) In cognitively impaired PD patients, any new symptom should prompt review of the entire medication burden for drugs with ACB scores above zero before adding new agents, including over-the-counter antihistamines and bladder agents
ANSWER: E
Rationale:
In patients with Parkinson's disease dementia, cognitive safety sits at the top of the management priority hierarchy. Because these patients have a severe cholinergic deficit — exceeding that of Alzheimer's disease — they are exquisitely sensitive to any additional anticholinergic burden. The correct clinical practice is to review the entire medication list, including over-the-counter medications, for anticholinergic burden using a validated tool such as the ACB scale whenever a new symptom appears that could plausibly reflect cognitive worsening. Medications with ACB scores above zero — including first-generation antihistamines (diphenhydramine), certain overactive bladder agents, muscle relaxants, and others — should be identified and deprescribed before new agents are added. Adding a new drug to address a symptom that is already being caused by the cumulative anticholinergic burden of existing medications treats the wrong problem.
Option A: Option A is incorrect because anticholinergic medications prescribed for somatic conditions reach the brain and contribute to cognitive impairment; their indication does not exempt them from ACB scoring.
Option B: Option B is incorrect because cognitively vulnerable patients may not reliably report or attribute cognitive worsening to medications; the clinician must proactively assess anticholinergic burden at every encounter, not wait for patient-reported complaints.
Option C: Option C is incorrect because the principle is not zero tolerance regardless of context — it is a systematic deprescribing review prioritized in cognitively vulnerable patients; some medications with low ACB scores may have essential indications that justify continued use after individual risk-benefit assessment.
Option D: Option D is incorrect because rivastigmine does not fully compensate for the cholinergic deficit in PDD, and additional anticholinergic burden continues to impair cognition in patients receiving cholinesterase inhibitor therapy; the ACB framework is directly applicable and especially important in PDD.
22. A neurologist is counseling the family of a 79-year-old man with Parkinson's disease dementia who has developed distressing visual hallucinations. She plans to initiate pimavanserin 34 mg once daily and explains the FDA-mandated black-box warning that accompanies this medication. Which of the following correctly describes that warning, and what additional cardiac safety consideration applies specifically to pimavanserin?
A) Pimavanserin carries a black-box warning for aplastic anemia requiring mandatory complete blood count monitoring every two weeks; the cardiac safety consideration is hypertensive crisis, which may occur in patients also taking levodopa
B) Pimavanserin carries a black-box warning for severe hepatotoxicity requiring liver function monitoring at baseline and every three months; the cardiac safety consideration is bradycardia, which occurs through serotonin-mediated slowing of the sinoatrial node
C) Pimavanserin carries a black-box warning for increased mortality in elderly patients with dementia-related psychosis — the same class warning that applies to all atypical antipsychotics — and QTc prolongation is an additional concern requiring a baseline electrocardiogram before initiation
D) Pimavanserin carries a black-box warning for severe impulse control disorders (pathological gambling, hypersexuality, binge eating) that emerge within the first four weeks of therapy; the cardiac safety consideration is atrial fibrillation triggered by serotonin 5-HT2A activation in the pulmonary veins
E) Pimavanserin carries a black-box warning for suicidality in patients under 65 years, identical to the warning carried by antidepressants; the cardiac safety consideration is supraventricular tachycardia mediated by serotonergic activation of cardiac pacemaker cells
ANSWER: C
Rationale:
Pimavanserin carries an FDA black-box warning for increased mortality in elderly patients with dementia-related psychosis — a class warning that applies to all antipsychotic agents used in this population, and which was applied to pimavanserin at approval despite its distinct mechanism (5-HT2A/2C inverse agonism rather than D2 blockade). This warning reflects data from multiple atypical antipsychotic trials showing approximately a 1.6- to 1.7-fold increase in all-cause mortality compared to placebo in elderly dementia patients, primarily from cardiovascular and infectious causes. QTc interval prolongation is an additional, pimavanserin-specific cardiac safety concern, and a baseline electrocardiogram to measure the QTc interval is appropriate before initiation. Pimavanserin should be used cautiously with other QTc-prolonging medications.
Option A: Option A is incorrect because aplastic anemia monitoring is required for clozapine, not pimavanserin; the mandatory monitoring required for clozapine is white blood cell count for agranulocytosis, and pimavanserin does not carry a hematological toxicity warning.
Option B: Option B is incorrect because pimavanserin does not carry a hepatotoxicity black-box warning, and bradycardia through serotonin-mediated SA node slowing is not the identified cardiac concern with pimavanserin.
Option D: Option D is incorrect because impulse control disorders are a recognized adverse effect of dopamine agonists in PD, not of pimavanserin, which has no dopaminergic activity; pimavanserin does not carry a black-box warning for impulse control disorders.
Option E: Option E is incorrect because the suicidality black-box warning applies to antidepressants in patients under 25 years of age (not 65), and pimavanserin does not carry this warning; supraventricular tachycardia mediated by serotonin on cardiac pacemaker cells is not the identified cardiac concern for this drug.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.